RenovoRx, Inc.

NasdaqCM RNXT

RenovoRx, Inc. Gross Profit for the Trailing 12 Months (TTM) ending September 30, 2024: USD 0.00

RenovoRx, Inc. Gross Profit is USD 0.00 for the Trailing 12 Months (TTM) ending September 30, 2024, a 0.00% change year over year. Gross profit is the difference between revenue and the cost of revenue, representing the profit earned from core business operations.

RenovoRx, Inc. Gross Profit for the Trailing 12 Months (TTM) ending September 30, 2023 was USD 0.00, a 100.00% change year over year.
RenovoRx, Inc. Gross Profit for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -10.00 K, a -100.00% change year over year.
RenovoRx, Inc. Gross Profit for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -5.00 K.

Key data

Date	Gross Profit	Operating Income	EBIT	EBITDA

NasdaqCM: RNXT

RenovoRx, Inc.

CEO	Mr. Shaun R. Bagai
IPO Date	Aug. 26, 2021
Location	United States
Headquarters	4546 El Camino Real
Employees	8
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

Key trends

Past 5 years